Sarepta Therapeutics (SRPT) Non-Current Debt (2010 - 2026)

Sarepta Therapeutics' Non-Current Debt history runs 17 years deep, the most recent figure standing at $838.2 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 26.37% year-over-year to $838.2 million in Q1 2026; TTM through Mar 2026 was $838.2 million, a 26.37% decrease from a year earlier, with the FY2025 full-year figure at $829.0 million, down 27.1% from the prior year.
• Non-Current Debt rose to $838.2 million in Q1 2026 per SRPT's latest filing, from $829.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $1.5 billion in Q4 2022 and bottomed at $829.0 million in Q4 2025.
• The 5-year median for Non-Current Debt is $1.1 billion (2025), against an average of $1.2 billion.
• Across the five-year window, Non-Current Debt surged 173.97% in 2022 and dropped 27.1% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $1.5 billion in 2022, then slipped by 19.83% to $1.2 billion in 2023, then fell by 8.15% to $1.1 billion in 2024, then declined by 27.1% to $829.0 million in 2025, then advanced by 1.11% to $838.2 million in 2026.
• Per Business Quant, the three latest SRPT Non-Current Debt figures stand at $838.2 million (Q1 2026), $829.0 million (Q4 2025), and $1.0 billion (Q3 2025).